The Latest Breaking News from Sanofi

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

We may think of air pollution as an outdoor problem, made up of car exhaust and smog. But if the air inside our homes is polluted, this can also affect our health.

Two flu vaccines are FDA-approved exclusively for people 65 and older, who are at higher risk of severe infection.

Officials say vaccination programme could prevent thousands of hospital admissions for babies

Shenzhen Component Index closed up 0.94%

Dr. Reddy's reported consolidated revenues of ₹7,673 crores (US$ 921 million) for Q1FY25, marking a 14% year-on-year increase and a 8% sequential growth.

Shenzhen Component Index closed down 0.31%

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell?

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

Blue-chip stocks offer stability and consistent growth irrespective of market conditions. Thus, blue chip names Lockheed Martin (LMT), Regeneron Pharmaceuticals (REGN), and Cigna Group (CI) could be prudent additions to your portfolios. These stocks are Strong Buy-rated in our proprietary POWR Ratings system. Read on.